Geoff Meacham
Stock Analyst at Citigroup
(4.44)
# 314
Out of 5,146 analysts
294
Total ratings
61.11%
Success rate
15.08%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $110 → $115 | $113.76 | +1.09% | 2 | Feb 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $15 → $19 | $14.37 | +32.22% | 6 | Feb 20, 2026 | |
| BIIB Biogen | Maintains: Neutral | $185 → $215 | $190.73 | +12.72% | 19 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $64 | $61.30 | +4.40% | 9 | Feb 6, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $115 → $120 | $122.46 | -2.01% | 11 | Feb 4, 2026 | |
| AMGN Amgen | Maintains: Neutral | $315 → $345 | $384.33 | -10.23% | 14 | Feb 4, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $235 → $230 | $226.92 | +1.36% | 22 | Jan 27, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $140 → $156 | $147.12 | +6.04% | 9 | Jan 27, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $48 → $50 | $45.15 | +10.74% | 4 | Jan 27, 2026 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $55 | $46.97 | +17.10% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $16.06 | +211.33% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $110 | $90.68 | +21.31% | 7 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $115 | $87.10 | +32.03% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $13.70 | +257.66% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $27.09 | -4.02% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.78 | +187.77% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $67.76 | +10.68% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $784.28 | -10.75% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $72 | $72.80 | -1.10% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $51.37 | -45.49% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $35.01 | +42.82% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $42.76 | +16.93% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $55.20 | +68.48% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $483.05 | +19.04% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $10.00 | +40.00% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $66.54 | -18.85% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $9.53 | -37.04% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $109.84 | +27.46% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $3.46 | -71.10% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $70.89 | +34.01% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $61.44 | +67.64% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.66 | +140.96% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $1,028.83 | +6.92% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $23.48 | -14.82% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $34.50 | -10.14% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $245.17 | -30.66% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.35 | +1,159.26% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.85 | +1,197.30% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $11.38 | -64.85% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.46 | +108.02% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.18 | +1,459.63% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.33 | +951.05% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $32.30 | +1,525.39% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.12 | +3,650.00% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $7.84 | +155.10% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.47 | +4,155.32% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $7.68 | +17.19% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $8.53 | +603.40% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $24.12 | -4.64% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $99.98 | -17.98% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $535.10 | -82.25% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $22.23 | +259.87% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $131.15 | +2.94% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.88 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.36 | +495.24% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $11.51 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $327.36 | -51.74% | 5 | Nov 8, 2017 |
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $113.76
Upside: +1.09%
Amylyx Pharmaceuticals
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $14.37
Upside: +32.22%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $185 → $215
Current: $190.73
Upside: +12.72%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $61.30
Upside: +4.40%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $115 → $120
Current: $122.46
Upside: -2.01%
Amgen
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $384.33
Upside: -10.23%
AbbVie
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $226.92
Upside: +1.36%
Gilead Sciences
Jan 27, 2026
Maintains: Buy
Price Target: $140 → $156
Current: $147.12
Upside: +6.04%
Royalty Pharma
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $45.15
Upside: +10.74%
Scholar Rock Holding
Jan 9, 2026
Initiates: Buy
Price Target: $55
Current: $46.97
Upside: +17.10%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $16.06
Upside: +211.33%
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $90.68
Upside: +21.31%
Dec 8, 2025
Maintains: Buy
Price Target: $98 → $115
Current: $87.10
Upside: +32.03%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $13.70
Upside: +257.66%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $27.09
Upside: -4.02%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.78
Upside: +187.77%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $67.76
Upside: +10.68%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $784.28
Upside: -10.75%
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $72.80
Upside: -1.10%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $51.37
Upside: -45.49%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $35.01
Upside: +42.82%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $42.76
Upside: +16.93%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $55.20
Upside: +68.48%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $483.05
Upside: +19.04%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $10.00
Upside: +40.00%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $66.54
Upside: -18.85%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $9.53
Upside: -37.04%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $109.84
Upside: +27.46%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $3.46
Upside: -71.10%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $70.89
Upside: +34.01%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $61.44
Upside: +67.64%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.66
Upside: +140.96%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $1,028.83
Upside: +6.92%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $23.48
Upside: -14.82%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $34.50
Upside: -10.14%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $245.17
Upside: -30.66%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.35
Upside: +1,159.26%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.85
Upside: +1,197.30%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $11.38
Upside: -64.85%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $13.46
Upside: +108.02%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.18
Upside: +1,459.63%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.33
Upside: +951.05%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $32.30
Upside: +1,525.39%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.12
Upside: +3,650.00%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $7.84
Upside: +155.10%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.47
Upside: +4,155.32%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $7.68
Upside: +17.19%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $8.53
Upside: +603.40%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $24.12
Upside: -4.64%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $99.98
Upside: -17.98%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $535.10
Upside: -82.25%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $22.23
Upside: +259.87%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $131.15
Upside: +2.94%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $8.88
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.36
Upside: +495.24%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $11.51
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $327.36
Upside: -51.74%